Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: a pattern-recognition1H NMR study

2005 ◽  
Vol 18 (1) ◽  
pp. 24-33 ◽  
Author(s):  
Victoria G. Dunne ◽  
Shermina Bhattachayya ◽  
Michael Besser ◽  
Caroline Rae ◽  
Julian L. Griffin
Keyword(s):  
Cerebrospinal Fluid ◽  
Clinical Outcome ◽  
Subarachnoid Haemorrhage ◽  
Aneurysmal Subarachnoid Haemorrhage ◽  
Nmr Study

Superoxide dismutase activity in cisternal cerebrospinal fluid after aneurysmal subarachnoid haemorrhage

1997 ◽  
Vol 139 (11) ◽  
pp. 1033-1037 ◽  
Author(s):  
P. Gaetani ◽  
C. Cafe ◽  
R. Rodriguez y Baena ◽  
F. Tancioni ◽  
C. Torri ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Superoxide Dismutase ◽  
Subarachnoid Haemorrhage ◽  
Superoxide Dismutase Activity ◽  
Aneurysmal Subarachnoid Haemorrhage

scholarly journals Correction: Soluble Toll-Like Receptors 2 and 4 in Cerebrospinal Fluid of Patients with Acute Hydrocephalus following Aneurysmal Subarachnoid Haemorrhage

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0157853
Author(s):  
Bartosz Sokół ◽  
Norbert Wąsik ◽  
Roman Jankowski ◽  
Marcin Hołysz ◽  
Barbara Więckowska ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Subarachnoid Haemorrhage ◽  
Aneurysmal Subarachnoid Haemorrhage ◽  
Toll Like Receptors ◽  
Acute Hydrocephalus

scholarly journals Increase of Soluble RAGE in Cerebrospinal Fluid following Subarachnoid Haemorrhage

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Bartosz Sokół ◽  
Norbert Wąsik ◽  
Roman Jankowski ◽  
Marcin Hołysz ◽  
Witold Mańko ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Subarachnoid Haemorrhage ◽  
Control Group ◽  
Aneurysmal Subarachnoid Haemorrhage ◽  
Pronounced Difference ◽  
Significance Threshold ◽  
Soluble Rage ◽  
Inflammatory Mechanism ◽  
Glycation End Products ◽  
Csf Levels

Receptors for advanced glycation end-products (RAGE) mediate the inflammatory reaction that follows aneurysmal subarachnoid haemorrhage. Soluble RAGE (sRAGE) may function as a decoy receptor. The significance of this endogenous anti-inflammatory mechanism in subarachnoid haemorrhage (SAH) remains unknown. The present study aims to analyse sRAGE levels in the cerebrospinal fluid (CSF) of SAH patients. sRAGE levels were assayed by ELISA kit in 47 CSF samples collected on post-SAH days 0–3, 5–7, and 10–14 from 27 SAH patients with acute hydrocephalus. CSF levels of sRAGE were compared with a control group and correlated with other monitored parameters. In the control group, the CSF contained only a trace amount of sRAGE. By contrast, the CSF of 20 SAH patients collected on post-SAH days 0–3 was found to contain statistically significant higher levels of sRAGE (mean concentration 3.91 pg/mL, p<0.001). The most pronounced difference in CSF sRAGE levels between good and poor outcome patients was found on days 0–3 post-SAH but did not reach the significance threshold (p=0.234). CSF sRAGE levels did not change significantly during hospitalisation (p=0.868) and correlated poorly with treatment outcome, systemic inflammatory markers, and other monitored parameters. Our study revealed an early and constant increase of sRAGE level in the CSF of SAH patients.

scholarly journals Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol

2022 ◽  
Author(s):  
Ben Gaastra ◽  
Sheila Alexander ◽  
Mark K. Bakker ◽  
Hemant Bhagat ◽  
Philippe Bijlenga ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Subarachnoid Haemorrhage ◽  
Association Study ◽  
Genome Wide Association Study ◽  
Statistical Significance ◽  
Genome Wide Association ◽  
Aneurysmal Subarachnoid Haemorrhage ◽  
Nucleotide Polymorphisms ◽  
Public Network ◽  
Genome Wide

AbstractAneurysmal subarachnoid haemorrhage (aSAH) results in persistent clinical deficits which prevent survivors from returning to normal daily functioning. Only a small fraction of the variation in clinical outcome following aSAH is explained by known clinical, demographic and imaging variables; meaning additional unknown factors must play a key role in clinical outcome. There is a growing body of evidence that genetic variation is important in determining outcome following aSAH. Understanding genetic determinants of outcome will help to improve prognostic modelling, stratify patients in clinical trials and target novel strategies to treat this devastating disease. This protocol details a two-stage genome-wide association study to identify susceptibility loci for clinical outcome after aSAH using individual patient-level data from multiple international cohorts. Clinical outcome will be assessed using the modified Rankin Scale or Glasgow Outcome Scale at 1–24 months. The stage 1 discovery will involve meta-analysis of individual-level genotypes from different cohorts, controlling for key covariates. Based on statistical significance, supplemented by biological relevance, top single nucleotide polymorphisms will be selected for replication at stage 2. The study has national and local ethical approval. The results of this study will be rapidly communicated to clinicians, researchers and patients through open-access publication(s), presentation(s) at international conferences and via our patient and public network.

Classification of non-aneurysmal subarachnoid haemorrhage: CT correlation to the clinical outcome

2010 ◽  
Vol 65 (8) ◽  
pp. 623-628 ◽  
Author(s):  
S. Nayak ◽  
A.B. Kunz ◽  
K. Kieslinger ◽  
G. Ladurner ◽  
M. Killer
Keyword(s):  
Clinical Outcome ◽  
Subarachnoid Haemorrhage ◽  
Aneurysmal Subarachnoid Haemorrhage
Sign in / Sign up

Export Citation Format

Share Document